ArticleAnnals of hematology2026

6-month Progression-Free Survival (PFS6) as a prognostic factor in large B-cell lymphoma patients undergoing chimeric antigen receptor T-cell therapy: A real-world multicenter study.

Zhangyan Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.